From science to scale: Accelerating biopharma execution and commercialisation

1 min read

Female scientist conducting research in a laboratory

A North American biopharmaceutical company approaching late-stage development and future commercialisation faced mounting complexity as it scaled rapidly. Legacy structures, slow decision-making and unclear accountability threatened execution across an expanding portfolio.  

  Insigniam partnered with senior leaders and product development teams to redesign the operating model, clarify governance and shift ownership closer to the work. Through a matrixed execution model and leadeship alignment, the organisation accelerated decisions, improved productivity by up to 200%, and etablished a culture of ownership and execution excellence – creating a scalable foundation for sustained commercial performance.

Outcome 1: Improved productivity by up to 200% by aligning priorities and clarifying the critical path, accelerating delivery across multiple programmes
Outcome 2: Shifted decision-making authority from senior leadership bottlenecks to empowered Product Development Teams, enabling faster, bolder and more confident execution
Outcome 3: Positioned the company for sustained, profitable growth by establishing a matrixed operating model with clear governance and defined ownership, creating a scalable foundation for commercialisation

The challenge

A 20-year-old biopharmaceutical company was approaching a defining inflection point. Long established as a clinical-stage, R&D-driven organisation, it was preparing for late-stage development and future commercialisation. The stakes were high: regulatory timelines, portfolio expansion and the need to deliver profitable growth for the first time. At the same time, the organisation nearly doubled in size, introducing new capabilities, expectations and pressure for speed. Structures, governance and ways of working that once supported scientific rigor were no longer sufficient. Without a fundamental shift, the company risked slowed execution, missed milestones and diminished commercial impact.

The company had reached a pivotal moment. Long defined by scientific rigor and a research-driven, function-based model, it was no longer built for commercial scale. With one product in development and several in the pipeline, it needed to evolve quickly into a viable biopharma enterprise. Rapid growth, nearly doubling headcount, introduced new expertise and higher expectations for speed, alongside tenured employees’ deep institutional knowledge. The resulting cultural friction, risk-averse habits and consensus-driven decision-making slowed execution. Overcrowded meetings, frequent escalations and siloed information created inefficiencies. Without structural change, the company faced delayed filings, postponed market entry and diminished profitability.

The approach

To catalyse transformation, we partnered with senior leaders and product development teams to reset how the organisation operated as it scaled, using our: Reveal, Unhook, Invent and Implement methodology. Through 54 stakeholder interviews, we surfaced cultural and structural patterns – consensus-driven decisions, unclear roles, legacy habits and commercialisation growing pains – that slowed execution and diluted accountability. Leaders unhooked from these constraints and co-designed a matrixed operating model with clear decision rights and governance. We then installed practical ways of working, shifted authority to empowered teams, aligned senior leadership and redesigned communication. The result: faster decisions, stronger ownership, improved coordination and consistent delivery across programmes.

The impact

The intervention fundamentally changed how the organisation operated as it scaled toward commercialisation. Decision-making moved closer to the work, enabling teams to act with greater confidence, speed and ownership. Senior leaders shifted from being bottlenecks to stewards of alignment, reinforcing clarity and trust across the enterprise. Product development teams evolved into accountable owners of outcomes, accelerating progress across multiple programs simultaneously.  

 Just as critically, the culture moved beyond consensus building to one defined by candid debate, clear priorities and execution excellence. The operating model, governance and behaviours installed created a scalable foundation – positioning the organisation to sustain performance, adapt as complexity increases and deliver on its commercial ambitions. 